Overactive Bladder Treatment Market Research Report: By Pharmacotherapy (Anticholinergic, Botox, Others), by Non-Pharmacological Treatment (Behavioral Therapy, Others), by Disease (Idiopathic Overactive Bladder, Others) - Forecast Till 2030

Overactive Bladder Treatment Market Overview:

The Overactive Bladder Treatment Market is projected to reach USD 3.4 Billion by 2030 at 3.70% CAGR during the forecast period 2022-2030. It is estimated that the overactive bladder treatment market is expected to register a USD 3.4 Billion at a 3.70% CAGR during the forecast period. The overactive bladder therapy market is projected to benefit from COVID-19. This is mostly due to an increase in the number of COVID-19 recovered patients experiencing overactive bladder symptoms. Patients are reported with de novo or increasing overactive bladder symptoms 10-14 weeks following hospitalization with COVID-19, according to a research titled Long COVID and COVID-19 Associated Cystitis (CAC) published in Springer Journal in 2021.

Furthermore, according to research released by the National Institute of Health (NIH) in 2020, COVID-19 infection causes an increase in urine cytokine levels, which leads to an increase in urination frequency, which leads to overactive bladder problems in patients infected with COVID-19. As a result, the rise in COVID-19 infection rates linked to overactive bladder symptoms raised the demand for overactive bladder treatments.

Market Research Future research is conducted by industry experts who offer insight into industry structure, market segmentation, treatment assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments and categories geographically presented are studied and are estimated based on primary and secondary research.

• Primary Research

Extensive primary research was conducted to gain a deeper insight into the market and the industry performance. In this particular report, we have conducted primary surveys (interviews) with the key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of the major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.

• Secondary Research

Secondary research was mainly used to collect and identify information useful for an extensive, technical, market-oriented, and commercial study of the overactive bladder treatment market. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, & developments related to the market and Treatment Perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company websites, the international organization of chemical manufacturers, some paid databases, and many others.

Company Profiles

• Astellas Pharma Inc.


• Pfizer, Inc.


• Teva Pharmaceutical


• Allergan, Plc. 


• Mylan N.V. 


• Endo International Plc 


• Hisamitsu Pharmaceutical Co., Inc.


• Sanofi S. A.


• Aurobindo Pharma Limited 


• Johnson & Johnson


• Intas Pharmaceuticals Ltd. 


• Apotex Inc. 


• Macleods Pharmaceuticals Ltd. 


• Medtronic PLC


• Cogentix Medical, Inc.


• Others

Segmentation

The global overactive bladder treatment market is segmented on the basis of pharmacotherapy, non-pharmacological treatment, and disease.

On the basis of pharmacotherapy, the market is classified into anticholinergics, Botox, mirabegron, neurostimulation, and others. Further, anticholinergics are classified into solifenacin, oxybutynin, fesoterodine, darifenacin, tolterodine, trospium, and others.

The overactive bladder treatment global market on the basis of non-pharmacological treatment is segmented into dietary and fluid modifications, behavioral therapy, pelvic floor muscle rehabilitation, and others.

On the basis of disease, the market is segmented into idiopathic overactive bladder and neurogenic overactive bladder. Further, the neurogenic overactive bladder is segmented into the overactive bladder in Parkinson’s disease, the overactive bladder in stroke, the overactive bladder in spinal cord injury, and the overactive bladder in other disorders.

Geographically, the overactive bladder treatment global market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The overactive bladder treatment market in the Americas is further segmented into North America and South America. North America is further classified as the US and Canada.

The overactive bladder treatment market in Europe is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe.

The overactive bladder treatment market in Asia-Pacific is segmented into Japan, China, India, Republic of Korea, Australia, and the rest of Asia-Pacific.

The overactive bladder treatment global market in the Middle East and Africa is segmented into the Middle East and Africa.

Regional Market Summary

The global overactive bladder treatment market consists of four regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa. North America is anticipated to dominate the market in the Americas owing to the increasing geriatric population, growing occurrences of OAB, and the availability of numerous healthcare coverage systems such as Medicare.

Europe is anticipated to hold the second position in the global overactive bladder treatment market. It is estimated that the market growth in this region is attributed to the rising incidences of OAB and availability of reimbursement for certain treatment options. For instance, the UK’s National Institutes for Health and Care Excellence (NICE) provides reimbursement for the Botox therapy.

The overactive bladder treatment market in Asia-Pacific consists of countries, namely, China, Japan, the Republic of Korea, India, Australia, and the rest of Asia-Pacific. The Asia-Pacific region is expected to be the fastest growing region owing to the growing prevalence of bladder overactivity, rising geriatric population, rising healthcare expenditure, and increasing awareness about overactive bladder condition.

The Middle East and Africa are likely to hold the least share in the global overactive bladder treatment market. In this region, the Middle East is expected to dominate owing to the rising healthcare expenditure and rising occurrences of neurological diseases, especially among the aged population.

Global Overactive Bladder Treatment Market, by Pharmacotherapy

• Anticholinergics


• Solifenacin


• Oxybutynin


• Fesoterodine


• Darifenacin


• Tolterodine


• Trospium


• Others


• Botox


• Mirabegron


• Neurostimulation


• Others

Global Overactive Bladder Treatment Market, by Non-Pharmacological Treatment

• Dietary and Fluid Modifications


• Behavioral Therapy


• Pelvic Floor Muscle Rehabilitation


• Others

Global Overactive Bladder Treatment Market, by Disease

• Idiopathic Overactive Bladder


• Neurogenic Overactive Bladder


• Overactive Bladder in Parkinson’s Disease


• Overactive Bladder in Stroke


• Overactive Bladder in Multiple Sclerosis


• Overactive Bladder in Spinal Cord Injury


• Overactive Bladder in Other Disorders

Global Overactive Bladder Treatment Market, by Region

• North America




• US


• Canada




• Europe




• Germany


• France


• UK


• Italy


• Spain


• Rest of Europe




• Asia-Pacific




• China


• Japan


• India


• Australia


• South Korea


• Rest of Asia-Pacific




• Rest of the World




• Middle East


• Africa


• Latin America

Recent Development

Allergan Ltd (Allergan) is a specialized pharmaceutical business that develops and sells branded medicines, biosimilars, and over-the-counter (OTC) pharmaceutical products. It is a subsidiary of AbbVie Inc. It sells items in the fields of eye care, dermatology, central nervous system, gastroenterology, women's health, urology, and anti-infective therapeutics. National retail medication and food store chains, mail order merchants, hospitals, clinics, government agencies, and managed healthcare providers such as health maintenance organizations and other institutions are among the customers of the company's products. It operates across the Americas, Europe, Asia-Pacific, the Middle East, and Africa, among other places. The headquarters of Allergan is in Dublin, Ireland.

Pfizer Inc. is a renowned pharmaceutical business that develops and sells drugs to treat a variety of ailments, including cardiovascular disease, cancer, immunological problems, and even uncommon diseases. In addition to sterile injectable medicines, active pharmaceutical ingredients (APIs), and biosimilars, the firm manufactures sterile injectable pharmaceuticals, APIs, and biosimilars. The product portfolio of this well-known pharmaceutical firm comprises a wide range of generic and proprietary medications, as well as APIs.Intended Audience

• Drug manufacturers, vendors, and distributors


• Academic and government research institutes


• Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs)


• Venture capitalists and investors